Comparable stake leader
VANGUARD CAPITAL MANAGEMENT LLC
SEC ownership of Edwards Lifesciences Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001099800.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
11 Sep 2026
- Public ticker
- EW on NYSE
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
VANGUARD CAPITAL MANAGEMENT LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
VANGUARD CAPITAL MANAGEMENT LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
11 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001099800
- Issuer location
- Irvine, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Edwards Lifesciences Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD CAPITAL MANAGEME...
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
11 Sep 2026
13D/G
13F
3/4/5
Lead comparable stake: 7.5%
13D/G row: VANGUARD CAPITAL MANAGEMENT LLC
Showing 1-8 of 50 holder rows.
Quick read
VANGUARD CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 7.5%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
VANGUARD CAPITAL MANAGEMENT LLC
7.5%
BlackRock, Inc.
7.5%
WELLINGTON MANAGEMENT GROUP LLP
3.4%
Scott B. Ullem
0.05%
Nicholas J. Valeriani
0.01%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
7.5%
|
$3,481,680,843
43,477,533 shares
|
$0 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.5%
from 13D/G
|
$5,318,092,039
58,789,433 shares
|
— | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
3.4%
|
$1,547,456,998
19,826,483 shares
|
$0 | 30 Jun 2025 |
| Scott B. Ullem |
3/4/5
CVP, Chief Financial Officer
|
0.05%
|
$25,069,684
313,058 shares
|
-$3,874,946 | 11 May 2026 |
| Nicholas J. Valeriani |
3/4/5
Director
|
0.01%
|
$6,760,593
84,423 shares
|
— | 08 May 2026 |
| Steven R. Loranger |
3/4/5
Director
|
0.01%
|
$6,756,268
84,369 shares
|
— | 08 May 2026 |
| Kieran Gallahue |
3/4/5
Director
|
0.01%
|
$6,724,397
83,971 shares
|
— | 08 May 2026 |
| Daveen Chopra |
3/4/5
CVP, TMTT, Surgical & IHFM
|
0.01%
|
$3,973,545
43,926 shares
|
-$3,190,095 | 11 Sep 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$27,736,914.
Buys
$0
Insiders: 0
Sells
$27,736,914
Insiders: 9
Net
-$27,736,914
Shares: -332,184
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 332,184
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 50,780 | $0 | $4,536,130 | -$4,536,130 |
| 3-6 | 0 | 84,544 | $0 | $6,908,711 | -$6,908,711 |
| 6-9 | 0 | 108,488 | $0 | $8,838,270 | -$8,838,270 |
| 9-12 | 0 | 88,372 | $0 | $7,453,804 | -$7,453,804 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to Edwards Lifesciences Corp. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
Michael A. Mussallem
Net 12M change
-$27,736,915
Latest report
08 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Michael A. Mussallem | Director | $341,985,766 | Mixed | 02 May 2024 | ||
| Scott B. Ullem | CVP, Chief Financial Officer | $25,069,684 | -$3,874,946 | -13% | Mixed | 11 May 2026 |
| Jean-Luc M. Lemercier | CVP, EMEACLA and JAPAC | $17,050,194 | Mixed | 07 Jul 2024 | ||
| Larry L. Wood | Global President TAVR & Surg | $16,163,469 | Mixed | 18 Aug 2025 | ||
| Donald E. Bobo Jr. | CVP,Strategy/Corp Development | $12,827,699 | -$11,153,191 | -47% | Mixed | 27 May 2026 |
| Bernard J. Zovighian | CEO, Director | $10,027,582 | -$6,997,244 | -41% | Mixed | 27 Jul 2026 |
| Theodora Mistras | CVP, Chief Financial Officer | $9,038,763 | Mixed | 09 Jul 2026 | ||
| Huimin Wang | CVP, Japan & Intercontinental | $7,520,181 | Mixed | 08 Jul 2022 | ||
| Nicholas J. Valeriani | Director | $6,760,593 | Mixed | 08 May 2026 | ||
| Steven R. Loranger | Director | $6,756,268 | Mixed | 08 May 2026 | ||
| Kieran Gallahue | Director | $6,724,397 | Mixed | 08 May 2026 | ||
| Catherine M. Szyman | CVP, Critical Care | $5,686,869 | Mixed | 03 Sep 2024 | ||
| Daveen Chopra | CVP, TMTT, Surgical & IHFM | $3,973,545 | -$3,190,095 | -45% | Mixed | 11 Sep 2026 |
| Daniel J. Lippis | Cvp, Tavr | $3,428,904 | -$924,639 | -21% | Filing P/S | 08 Oct 2026 |
| Robert W.a. Sellers | SVP, Corporate Controller | $3,251,149 | Mixed | 11 May 2024 | ||
| Heisz Leslie Stone | Director | $2,738,655 | -$218,120 | -7.4% | Mixed | 08 May 2026 |
| Martha H. Marsh | Director | $2,412,360 | Mixed | 12 May 2023 | ||
| Wayne Markowitz | Cvp, Japac | $1,752,260 | -$1,042,386 | -37% | Mixed | 11 Sep 2026 |
| Ramona Sequeira | Director | $1,670,068 | Mixed | 08 May 2026 | ||
| Annette Bruls | Cvp, Emeacla | $1,618,200 | -$237,907 | -13% | Filing P/S | 28 Aug 2026 |
Recent insider transactions for Edwards Lifesciences Corp
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Daniel J. Lippis | EW | Common Stock | Sale | -1.52% | $53,017 | $85.65 | -619 | 40,034 | 08 Oct 2026 | Direct |
| Daniel J. Lippis | EW | Common Stock | Options Exercise | 1.55% | 619 | 40,653 | 08 Oct 2026 | Direct | ||
| Daniel J. Lippis | EW | Employee Stock Option (Right to Acquire) | Options Exercise | -16.7% | -619 | 3,095 | 08 Oct 2026 | Direct | ||
| Wayne Markowitz | EW | Common Stock | Tax liability | -2.85% | -568 | 19,371 | 14 Sep 2026 | Direct | ||
| Andrew M. Dahl | EW | Common Stock | Tax liability | -1.7% | -253 | 14,615 | 13 Sep 2026 | Direct | ||
| Wayne Markowitz | EW | Common Stock | Tax liability | -1.75% | -355 | 19,939 | 11 Sep 2026 | Direct | ||
| Daveen Chopra | EW | Common Stock | Tax liability | -0.9% | -398 | 43,926 | 11 Sep 2026 | Direct | ||
| Daniel J. Lippis | EW | Common Stock | Sale | -1.52% | $54,169 | $87.51 | -619 | 40,034 | 11 Sep 2026 | Direct |
| Daniel J. Lippis | EW | Common Stock | Options Exercise | 1.55% | 619 | 40,653 | 11 Sep 2026 | Direct | ||
| Daniel J. Lippis | EW | Employee Stock Option (Right to Acquire) | Options Exercise | -14.3% | -619 | 3,714 | 11 Sep 2026 | Direct | ||
| Andrew M. Dahl | EW | Common Stock | Sale | -3.53% | $49,534 | $91.06 | -544 | 14,868 | 31 Aug 2026 | Direct |
| Annette Bruls | EW | Common Stock | Sale | -12.8% | $237,907 | $89.98 | -2,644 | 17,984 | 28 Aug 2026 | Direct |
| Daveen Chopra | EW | Common Stock | Sale | -41.8% | $2,894,440 | $91.02 | -31,800 | 44,324 | 26 Aug 2026 | Direct |
| Daveen Chopra | EW | Common Stock | Options Exercise | 71.7% | 31,800 | 76,124 | 26 Aug 2026 | Direct | ||
| Daveen Chopra | EW | Employee Stock Option (Right to Acquire) | Options Exercise | -100% | -31,800 | 0 | 26 Aug 2026 | Direct | ||
| Wayne Markowitz | EW | Common Stock | Sale | -5.76% | $113,417 | $91.46 | -1,240 | 20,294 | 26 Aug 2026 | Direct |
| Daniel J. Lippis | EW | Common Stock | Sale | -1.52% | $56,967 | $92.03 | -619 | 40,034 | 11 Aug 2026 | Direct |
| Daniel J. Lippis | EW | Common Stock | Options Exercise | 1.55% | 619 | 40,653 | 11 Aug 2026 | Direct | ||
| Daniel J. Lippis | EW | Employee Stock Option (Right to Acquire) | Options Exercise | -12.5% | -619 | 4,333 | 11 Aug 2026 | Direct | ||
| Wayne Markowitz | EW | Common Stock | Sale | -0.67% | $12,588 | $86.03 | -146 | 21,534 | 30 Jul 2026 | Direct |
| Wayne Markowitz | EW | Common Stock | Sale | -30.8% | $818,958 | $85.06 | -9,628 | 21,680 | 28 Jul 2026 | Direct |
| Wayne Markowitz | EW | Common Stock | Options Exercise | 44.4% | 9,628 | 31,308 | 28 Jul 2026 | Direct | ||
| Wayne Markowitz | EW | Employee Stock Option (Right to Acquire) | Options Exercise | -50% | -9,628 | 9,628 | 28 Jul 2026 | Direct | ||
| Bernard J. Zovighian | EW | Common Stock | Sale | -24.7% | $245,134 | $83.93 | -2,921 | 8,916 | 27 Jul 2026 | By Trust |
| Bernard J. Zovighian | EW | Common Stock | Gift | 2.78% | 320 | 11,836 | 27 Jul 2026 | By Trust | ||
| Bernard J. Zovighian | EW | Common Stock | Gift | -0.32% | -320 | 98,845 | 27 Jul 2026 | Direct | ||
| Annette Bruls | EW | Common Stock | Tax liability | -0.53% | -109 | 20,628 | 11 Jul 2026 | Direct | ||
| Daniel J. Lippis | EW | Common Stock | Sale | -1.52% | $56,762 | $91.70 | -619 | 40,034 | 10 Jul 2026 | Direct |
| Daniel J. Lippis | EW | Common Stock | Options Exercise | 1.55% | 619 | 40,653 | 10 Jul 2026 | Direct | ||
| Daniel J. Lippis | EW | Employee Stock Option (Right to Acquire) | Options Exercise | -11.1% | -619 | 4,952 | 10 Jul 2026 | Direct | ||
| Theodora Mistras | EW | Common Stock | Award | 99,920 | 99,920 | 09 Jul 2026 | Direct | |||
| Theodora Mistras | EW | Performance Rights | Award | 12,325 | 12,325 | 09 Jul 2026 | Direct | |||
| Theodora Mistras | EW | Employee Stock Option (Right to Acquire) | Award | 61,800 | 61,800 | 09 Jul 2026 | Direct | |||
| Daniel J. Lippis | EW | Common Stock | Tax liability | -0.93% | -377 | 40,034 | 07 Jul 2026 | Direct | ||
| Daniel J. Lippis | EW | Common Stock | Sale | -1.51% | $56,577 | $91.40 | -619 | 40,411 | 30 Jun 2026 | Direct |
| Daniel J. Lippis | EW | Common Stock | Options Exercise | 1.53% | 619 | 41,030 | 30 Jun 2026 | Direct | ||
| Daniel J. Lippis | EW | Employee Stock Option (Right to Acquire) | Options Exercise | -10% | -619 | 5,571 | 30 Jun 2026 | Direct | ||
| Bernard J. Zovighian | EW | Common Stock | Sale | -4.34% | $45,982 | $87.92 | -523 | 11,517 | 17 Jun 2026 | By Trust |
| Andrew M. Dahl | EW | Common Stock | Sale | -3.57% | $48,853 | $86.08 | -568 | 15,334 | 29 May 2026 | Direct |
| Donald E. Bobo Jr. | EW | Common Stock | Sale | -19% | $2,000,193 | $86.42 | -23,145 | 98,611 | 27 May 2026 | By Trust |
| Daveen Chopra | EW | Common Stock | Sale | -3.27% | $126,905 | $84.60 | -1,500 | 44,324 | 22 May 2026 | Direct |
| Daniel J. Lippis | EW | Common Stock | Sale | -1.51% | $50,307 | $81.14 | -620 | 40,411 | 18 May 2026 | Direct |
| Daniel J. Lippis | EW | Common Stock | Options Exercise | 1.53% | 620 | 41,031 | 18 May 2026 | Direct | ||
| Daniel J. Lippis | EW | Employee Stock Option (Right to Acquire) | Options Exercise | -9.1% | -620 | 6,190 | 18 May 2026 | Direct | ||
| Donald E. Bobo Jr. | EW | Common Stock | Sale | -20.5% | $654,573 | $81.82 | -8,000 | 30,970 | 15 May 2026 | 401(k) |
| Donald E. Bobo Jr. | EW | Common Stock | Sale | -30.4% | $818,106 | $82.07 | -9,968 | 22,798 | 15 May 2026 | Direct |
| Bernard J. Zovighian | EW | Common Stock | Sale | -75.1% | $2,833,013 | $77.93 | -36,351 | 12,040 | 12 May 2026 | By Trust |
| Bernard J. Zovighian | EW | Common Stock | Gift | 122.5% | 26,640 | 48,391 | 12 May 2026 | By Trust | ||
| Bernard J. Zovighian | EW | Common Stock | Gift | -21.2% | -26,640 | 99,165 | 12 May 2026 | Direct | ||
| Bernard J. Zovighian | EW | Common Stock | Tax liability | -17.2% | -26,198 | 125,805 | 11 May 2026 | Direct |
* marks a reported price that did not pass the local price check.